CA3172987A1 - Inhibiteurs a petites molecules de chd1l oncogenes presentant une activite preclinique contre le cancer colorectal - Google Patents

Inhibiteurs a petites molecules de chd1l oncogenes presentant une activite preclinique contre le cancer colorectal Download PDF

Info

Publication number
CA3172987A1
CA3172987A1 CA3172987A CA3172987A CA3172987A1 CA 3172987 A1 CA3172987 A1 CA 3172987A1 CA 3172987 A CA3172987 A CA 3172987A CA 3172987 A CA3172987 A CA 3172987A CA 3172987 A1 CA3172987 A1 CA 3172987A1
Authority
CA
Canada
Prior art keywords
group
chd1l
alkyl
inhibitor
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3172987A
Other languages
English (en)
Inventor
Daniel V. Labarbera
Joshua M. ABBOTT
Qiong ZHOU
Hector ESQUER
Brett Joseph PRIGARO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado
Original Assignee
University of Colorado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado filed Critical University of Colorado
Publication of CA3172987A1 publication Critical patent/CA3172987A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne le traitement de cancers induits par CHD1L, notamment des cancers induits par transcription TCF et des cancers induits par EMT à l'aide d'inhibiteurs de CHD1L. Des Inhibiteurs à petites molécules de CHD1L qui inhibent L'ATPase CHD1L et inhibent la transcription TCF dépendante de CHD1L ont été identifiés. Les inhibiteurs de CHD1L empêchent le complexe TCF de se lier à des éléments de réponse Wnt et à des sites promoteurs. Plus particulièrement, les inhibiteurs de CHD1L induisent la réversion d'EMT. Les inhibiteurs de CHD1L sont utiles dans le traitement de divers cancers et en particulier le CCR et le CCRm. Le cancer induit par CHD1L est, entre autres, le CCR, le cancer du sein, le gliome, le cancer du foie, le cancer du poumon ou les cancers gastro-intestinaux (GI). L'invention concerne également des inhibiteurs de CHD1L de formules I et XX et des sels associés tels que définis dans la description, ainsi que des compositions pharmaceutiques contenant des inhibiteurs de CHD1L. L'invention concerne également des combinaisons synergiques d'inhibiteurs de CHD1L avec d'autres agents antinéoplasiques.
CA3172987A 2020-03-24 2021-03-24 Inhibiteurs a petites molecules de chd1l oncogenes presentant une activite preclinique contre le cancer colorectal Pending CA3172987A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062994259P 2020-03-24 2020-03-24
US62/994,259 2020-03-24
US202163139394P 2021-01-20 2021-01-20
US63/139,394 2021-01-20
PCT/US2021/023981 WO2021195279A2 (fr) 2020-03-24 2021-03-24 Inhibiteurs à petites molécules de chd1l oncogènes présentant une activité préclinique contre le cancer colorectal

Publications (1)

Publication Number Publication Date
CA3172987A1 true CA3172987A1 (fr) 2021-09-30

Family

ID=77892666

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3172987A Pending CA3172987A1 (fr) 2020-03-24 2021-03-24 Inhibiteurs a petites molecules de chd1l oncogenes presentant une activite preclinique contre le cancer colorectal

Country Status (6)

Country Link
EP (1) EP4127209A2 (fr)
JP (1) JP2023520330A (fr)
CN (1) CN115667553A (fr)
AU (1) AU2021244209A1 (fr)
CA (1) CA3172987A1 (fr)
WO (1) WO2021195279A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023055763A2 (fr) * 2021-09-30 2023-04-06 The Regents Of The University Of Colorado, A Body Corporate Inhibiteurs à petites molécules de chd1l oncogènes présentant une activité préclinique contre le cancer colorectal
CN114457007B (zh) * 2022-02-28 2024-05-28 合肥燃音生物科技有限公司 一种基于微孔板的均一的单类器官模型及其制备方法
WO2023213833A1 (fr) * 2022-05-02 2023-11-09 Eisbach Bio Gmbh Utilisation d'inhibiteurs d'alc1 et synergie avec parpi
CN115290774B (zh) * 2022-07-21 2023-07-21 重庆医科大学 尿苷二磷酸葡萄糖醛酸在制备用于检测肝癌试剂中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012166722A1 (fr) * 2011-06-03 2012-12-06 The General Hospital Corporation Traitement du cancer colorectal, pancréatique et pulmonaire
WO2014205105A1 (fr) * 2013-06-19 2014-12-24 The Regents Of The University Of California Biomarqueurs de réponse à l'inhibition de poly(adp-ribose) polymérase (parp) dans un cancer

Also Published As

Publication number Publication date
CN115667553A (zh) 2023-01-31
WO2021195279A2 (fr) 2021-09-30
AU2021244209A1 (en) 2022-11-03
EP4127209A2 (fr) 2023-02-08
JP2023520330A (ja) 2023-05-17
WO2021195279A3 (fr) 2021-11-11

Similar Documents

Publication Publication Date Title
JP2021020957A (ja) 二官能性分子によって標的化タンパク質分解を誘導する方法
Li et al. Discovery of N 1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo [2, 3-d] pyrimidin-2-yl) amino) phenyl)-N 8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
CA3172987A1 (fr) Inhibiteurs a petites molecules de chd1l oncogenes presentant une activite preclinique contre le cancer colorectal
WO2017101803A1 (fr) Nouveau double inhibiteur de egfr et de alk
PH12015502737B1 (en) Novel fused pyrimidine compound or salt thereof
WO2018133795A1 (fr) Inhibiteur de l'ezh2 et son utilisation
Lv et al. Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors
KR20170003688A (ko) 단백질 탈아세틸화효소 억제제 및 이중 단백질 탈아세틸화효소-단백질 키나제 억제제로서의 헤테로사이클릭 하이드록삼산 및 그 이용 방법
Huang et al. Pyrido [2, 3-d] pyrimidin-7 (8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors
CA2805658C (fr) Polytherapie basee sur des inhibiteurs de mdm2 et efgr
Chen et al. Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth in vitro and in vivo
Zhang et al. Discovery of a series of N-(5-(quinolin-6-yl) pyridin-3-yl) benzenesulfonamides as PI3K/mTOR dual inhibitors
Dai et al. Antitumor activity and mechanisms of dual EGFR/DNA-targeting strategy for the treatment of lung cancer with EGFRL858R/T790M mutation
Li et al. Design, synthesis and biological evaluation of a new class of 7H-pyrrolo [2, 3-d] pyrimidine derivatives as Mps1 inhibitors for the treatment of breast cancer
Wang et al. Synthesis and biological evaluation of 7H-pyrrolo [2, 3-d] pyrimidine derivatives as potential p21-activated kinase 4 (PAK4) inhibitors
Hu et al. Discovery of pyrazolo [3, 4-b] pyridine derivatives as novel and potent Mps1 inhibitors for the treatment of cancer
JP2018513214A (ja) 新規なキナーゼ阻害剤の調製と使用
JP2015522048A (ja) 癌の処置および免疫抑制のための併用療法
EP4192826A1 (fr) Petites molécules pour le traitement de maladies auto-immunes et du cancer
US20230103444A1 (en) Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer
CA3233398A1 (fr) Inhibiteurs a petites molecules de la chd1l oncogene presentant une activite preclinique contre le cancer colorectal
Yuan et al. Pioneering 4, 11-Dioxo-4, 11-dihydro-1 H-anthra [2, 3-d] imidazol-3-ium Compounds as Promising Survivin Inhibitors by Targeting ILF3/NF110 for Cancer Therapy
WO2019095066A1 (fr) Thiénoisoquinolines et leurs dérivés pour le ciblage de tubuline, ch-tog, aurora a kinase, tpx2, cdk5rap2 et/ou aspm
US11801243B2 (en) Bromodomain inhibitors for androgen receptor-driven cancers
RU2810215C2 (ru) Ингибиторы рецепторов erbb

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220922

EEER Examination request

Effective date: 20220922

EEER Examination request

Effective date: 20220922

EEER Examination request

Effective date: 20220922

EEER Examination request

Effective date: 20220922

EEER Examination request

Effective date: 20220922

EEER Examination request

Effective date: 20220922

EEER Examination request

Effective date: 20220922